Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review
Background: Herb–drug interactions are nowadays an important decision factor in many healthcare interventions. Patients with cardiovascular risk factors such as hyperlipidemia and hypertension are usually prescribed long-term treatments. We need more informed decision tools to direct future clinical...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Plants |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2223-7747/12/3/623 |
| _version_ | 1827759659229904896 |
|---|---|
| author | Jose M. Prieto-Garcia Louise Graham Osamah Alkhabbaz Andre L. D. A. Mazzari |
| author_facet | Jose M. Prieto-Garcia Louise Graham Osamah Alkhabbaz Andre L. D. A. Mazzari |
| author_sort | Jose M. Prieto-Garcia |
| collection | DOAJ |
| description | Background: Herb–drug interactions are nowadays an important decision factor in many healthcare interventions. Patients with cardiovascular risk factors such as hyperlipidemia and hypertension are usually prescribed long-term treatments. We need more informed decision tools to direct future clinical research and decision making to avoid HDI occurrences in this group. Methods: A scoping review was conducted using data from online databases such as PUBMED, the National Library of Medicine, and the electronic Medicines Compendium. Included studies consisted of the reported effects on Phase 1/2 and P-glycoprotein of herbal medicines listed in the medicines agencies of Latin America and Europe and drugs used for cardiovascular conditions (statins, diuretics, beta blockers, calcium channel blockers, and ACE inhibitors). The cross tabulation of the results allowed for finding potential HDI. Results and conclusions: as per the preclinical data reviewed here, we encourage more clinical research on whether drugs with apparently very low interaction risk, such as pravastatin, nadolol, and nimodipine/nitrendipine, may help prevent HDI when statins, beta blockers, and calcium channel blockers, respectively, are prescribed for long-term treatments. |
| first_indexed | 2024-03-11T09:29:50Z |
| format | Article |
| id | doaj.art-d8ce134b86854548898279b2b6a84851 |
| institution | Directory Open Access Journal |
| issn | 2223-7747 |
| language | English |
| last_indexed | 2024-03-11T09:29:50Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Plants |
| spelling | doaj.art-d8ce134b86854548898279b2b6a848512023-11-16T17:45:04ZengMDPI AGPlants2223-77472023-01-0112362310.3390/plants12030623Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping ReviewJose M. Prieto-Garcia0Louise Graham1Osamah Alkhabbaz2Andre L. D. A. Mazzari3Centre for Natural Products Discovery, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UKCentre for Natural Products Discovery, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UKCentre for Natural Products Discovery, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, UKSchool of Pharmacy, University College London, London WC1N 1AX, UKBackground: Herb–drug interactions are nowadays an important decision factor in many healthcare interventions. Patients with cardiovascular risk factors such as hyperlipidemia and hypertension are usually prescribed long-term treatments. We need more informed decision tools to direct future clinical research and decision making to avoid HDI occurrences in this group. Methods: A scoping review was conducted using data from online databases such as PUBMED, the National Library of Medicine, and the electronic Medicines Compendium. Included studies consisted of the reported effects on Phase 1/2 and P-glycoprotein of herbal medicines listed in the medicines agencies of Latin America and Europe and drugs used for cardiovascular conditions (statins, diuretics, beta blockers, calcium channel blockers, and ACE inhibitors). The cross tabulation of the results allowed for finding potential HDI. Results and conclusions: as per the preclinical data reviewed here, we encourage more clinical research on whether drugs with apparently very low interaction risk, such as pravastatin, nadolol, and nimodipine/nitrendipine, may help prevent HDI when statins, beta blockers, and calcium channel blockers, respectively, are prescribed for long-term treatments.https://www.mdpi.com/2223-7747/12/3/623BrazilEuropeherb–drug interactionscardiovascularhypertensionhyperlipidemia |
| spellingShingle | Jose M. Prieto-Garcia Louise Graham Osamah Alkhabbaz Andre L. D. A. Mazzari Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review Plants Brazil Europe herb–drug interactions cardiovascular hypertension hyperlipidemia |
| title | Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review |
| title_full | Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review |
| title_fullStr | Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review |
| title_full_unstemmed | Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review |
| title_short | Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review |
| title_sort | potential pharmacokinetic interactions of common cardiovascular drugs and selected european and latin american herbal medicines a scoping review |
| topic | Brazil Europe herb–drug interactions cardiovascular hypertension hyperlipidemia |
| url | https://www.mdpi.com/2223-7747/12/3/623 |
| work_keys_str_mv | AT josemprietogarcia potentialpharmacokineticinteractionsofcommoncardiovasculardrugsandselectedeuropeanandlatinamericanherbalmedicinesascopingreview AT louisegraham potentialpharmacokineticinteractionsofcommoncardiovasculardrugsandselectedeuropeanandlatinamericanherbalmedicinesascopingreview AT osamahalkhabbaz potentialpharmacokineticinteractionsofcommoncardiovasculardrugsandselectedeuropeanandlatinamericanherbalmedicinesascopingreview AT andreldamazzari potentialpharmacokineticinteractionsofcommoncardiovasculardrugsandselectedeuropeanandlatinamericanherbalmedicinesascopingreview |